Incorporation of Dosimetric Gradients and Parotid Gland Migration Into Xerostomia Prediction

• Published in: Frontiers in oncology Vol. 9; p. 697
• Main Authors: Astaburuaga, Rosario, Gabryś, Hubert S, Sánchez-Nieto, Beatriz, Floca, Ralf O, Klüter, Sebastian, Schubert, Kai, Hauswald, Henrik, Bangert, Mark
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 31.07.2019
• Subjects: anatomical changes; daily MVCT; dosimetric changes; head and neck cancer; intensity-modulated radiotherapy; Oncology; xerostomia; intensity-modulated radiotherapy; dosimetric changes; head and neck cancer; normal tissue-complication probability; xerostomia; anatomical changes; daily MVCT
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2019.00697

Due to the sharp gradients of intensity-modulated radiotherapy (IMRT) dose distributions, treatment uncertainties may induce substantial deviations from the planned dose during irradiation. Here, we investigate if the planned mean dose to parotid glands in combination with the dose gradient and information about anatomical changes during the treatment improves xerostomia prediction in head and neck cancer patients. Eighty eight patients were retrospectively analyzed. Three features of the contralateral parotid gland were studied in terms of their association with the outcome, i.e., grade ≥ 2 (G2) xerostomia between 6 months and 2 years after radiotherapy (RT): planned mean dose (MD), average lateral dose gradient (GRADX), and parotid gland migration toward medial (PGM). PGM was estimated using daily megavoltage computed tomography (MVCT) images. Three logistic regression models where analyzed: based on (1) MD only, (2) MD and GRADX, and (3) MD, GRADX, and PGM. Additionally, the cohort was stratified based on the median value of GRADX, and a univariate analysis was performed to study the association of the MD with the outcome for patients in low- and high-GRADX domains. The planned MD failed to recognize G2 xerostomia patients (AUC = 0.57). By adding the information of GRADX (second model), the model performance increased to AUC = 0.72. The addition of PGM (third model) led to further improvement in the recognition of the outcome (AUC = 0.79). Remarkably, xerostomia patients in the low-GRADX domain were successfully identified (AUC = 0.88) by the MD alone. Our results indicate that GRADX and PGM, which together serve as a proxy of dosimetric changes, provide valuable information for xerostomia prediction.